Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue tetravalent vaccine (live, attenuated) (Instituto Butantan)
- Development stage
- Unknown
- Lead developer
- Instituto Butantan
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Butantan-DV is a live attenuated tetravalent vaccine developed by the Butantan Institute in collaboration with the US National Institutes of Health (NIH). It is designed to prevent dengue fever caused by all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine consists of four specific attenuated strains: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30. It is administered as a single subcutaneous dose and has demonstrated efficacy in Phase 3 clinical trials across a broad age range (2–59 years), regardless of prior dengue exposure. The vaccine stimulates a broad neutralizing antibody immune response and is currently being evaluated in Phase 4 trials for specific populations, such as those with autoimmune rheumatic diseases.
- Brand names
- Butantan-DV
- Other names
- Butantan Dengue VaccineNIH TV003TetraVax-DV
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on dengue tetravalent vaccine (live, attenuated) (Instituto Butantan).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue tetravalent vaccine (live, attenuated) (Instituto Butantan).